Treat a Double Chin without Liposuction: KYBELLA is the Key
Quite often, a double chin can negatively impact the overall appearance of one’s face and results in a person feeling older, and heavier, than they actually are. There’s good news…
Sunset Cosmetic Surgery now has Kybella — an FDA approved injectable treatment that works to reduce submental neck fat (aka a double chin) without surgery. No incision, no surgery, no downtime. Kybella involves a series of injections which work to reduce the fat in the areas injected.
Kybella was approved in the U.S. by the FDA in the Spring of 2015. It is the first and only approved treatment for the reduction of submental fullness, or a double chin, without the necessity for surgery. Its special formulation is an identical make up of deoxycholic acid, which is a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into subcutaneous fat, Kybella causes the destruction of fat cells. Once destroyed, those cells are unable to store or accumulate fat. Patients treated, ften respond positively, reporting an improvement in the amount of fat in the area under the chin, as well as an enhanced emotional impact when asked how happy, bothered, self-conscious, embarrassed, old and overweight they felt following treatment. Kybella is not recommended for the safe and effective use as a treatment of subcutaneous fat outside of the submental region.
Kybella Before & After Photos
The above images are unaltered photographs of a patient treated with Kybella. Individual results may vary. Photo courtesy: Allergan.
How much does Kybella cost?
For optimum results, KYBELLA™ requires 2 vials per session, with at least 3-4 sessions total for optimal results (but no more than 6). Pricing is as follows: Session 1: $750/vial Session 2: $700/vial Sessions 3+: $650/vial Please note Sunset provides numbing cream and/or numbing injections FREE OF CHARGE for all injectable treatments, while some offices require you to purchase it separately.
Typical recovery time
Sunset’s Los Angeles Kybella treatments are administered by our double-board certified surgeons. Kybella is administered by injection into the fat under the chin and is tailored to individual treatment goals. There is no down time associated with Los Angeles Kybella treatments. Each session lasts aprpoximately 30 minutes and can be performed directly in our office — allowing one to get back to work or resume immediate activity.
How long do Kybella treatments last?
Many patients experienced visible results in two to four treatments. Up to six treatments may be administered. Once the aesthetic response is achieved, retreatment is not expected.
What are the side effects and risks of Los Angeles Kybella treatments?
Unwanted side effects are rare with Kybella, but may include swelling, bruising, pain, numbness, redness and areas of hardness in the treatment area. Contact us immediately if you experience any of these side effects.
Other Safety Information
KYBELLA™ (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. The safe and effective use of KYBELLA™ for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended. Important Safety Information KYBELLA™ should only be administered by a trained healthcare professional. KYBELLA™ is contraindicated in the presence of infection at the injection sites. Avoid injecting in proximity to vulnerable anatomic structures due to the increased risk of tissue damage. Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported during clinical trials. To avoid the potential for nerve injury, KYBELLA™ should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve. All marginal mandibular nerve injuries reported from the trials resolved spontaneously (range 1-298 days, median 44 days). Difficulty swallowing (dysphagia) occurred in the clinical trials in the setting of administration site reactions, e.g., pain, swelling, and induration of the submental area. Cases of dysphagia spontaneously resolved (range 1-81 days, median 3 days). Subjects with current or prior history of dysphagia were excluded from clinical trials. Avoid use of KYBELLA™ in these patients as current or prior history of dysphagia may exacerbate the condition. In clinical trials, 72% of subjects treated with KYBELLA™ experienced injection site hematoma/bruising. KYBELLA™ should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur. To avoid the potential of tissue damage, KYBELLA™ should not be injected into or in close proximity (1-1.5 cm) to salivary glands, lymph nodes and muscles. The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.